Based on these results, two-sample and two-step Mendelian randomization (MR) analyses using blood expression quantitative trait loci instruments were conducted to evaluate the causal effect of NEU1 inhibition-the key celecoxib target-on cervical cancer risk and to assess immune cell mediation.<h4>Results</h4>Celecoxib significantly inhibited cervical cancer cell proliferation, migration, colony formation, and invasion. This evidence concerns the gene NEU1 and cervical carcinoma.